[{"orgOrder":0,"company":"Infinimmune","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"IFX-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinimmune \/ Infinimmune","highestDevelopmentStatusID":"4","companyTruncated":"Infinimmune \/ Infinimmune"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Grid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Infinimmune \/ Grid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Grid Therapeutics"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Infinimmune \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Playground Global"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Immunome","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinimmune \/ Immunome","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Immunome"}]